 Brickell Biotech, Inc. Brickell BBI, a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. Brickell has continued to make progress during the first quarter of 2020, and we remain committed to advancing sofpironium bromide into Phase 3 clinical studies in the U.S., commented Robert Brown, Chief Executive Officer of Brickell. Today, Brickell announced that, based on a preliminary review of the top-line results from the 12-month Phase 3 open-label long-term safety study, in 300 subjects 9 years old with primary axillary hyperhidrosis, sofpironium bromide gel, 5 and 15 was safe and generally well tolerated, which was consistent with the earlier Phase 2 clinical trial results. 